The German Breast Group’s newsroom
Our newsroom provides you with the latest information about the German Breast Group. This section of the website also includes photographic material and information about our events. In addition, our Annual Scientific Reports, which provide an overview of our research activities, can be downloaded here.
-
05.05.2023 GBG Research at ESMO-BC 2023
GBG Research at ESMO-Breast Cancer Conference 2023 in Berlin
-
28.02.2023 Annual Scientific Report 2022 published
Our Annual Scientific Report 2022 provides a concise overview of current study findings along with important lectures and research posters presented by our members from the last year.
-
24.01.2023 Save the date: 20th GBG Annual Meeting 2023
The 20th GBG Annual Meeting 2023 will start 2nd to 3rd of March 2023 at the Steigenberger Airport Hotel
-
23.01.2023 St.Gallen International Breast Cancer Conference 2023
The 18th St.Gallen International Breast Cancer Conference 2023 will take place from 15 – 18 March 2023 in Vienna / Austria as a hybrid conference, allowing both in-person and virtual access
-
18.11.2022 Desiree: dose escalation of everolimus published
We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.
-
08.11.2022 GBG research at SABCS 2022
We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10
-
14.10.2022 Location of Subcutaneous Trastuzumab Injection
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study
-
02.09.2022 August 2022 : Neoadjuvant durvalumab improves survival in early triple-negative breast cancer despite a modest pCR increase – follow-up data from GeparNuevo trial
We are pleased to inform you that long-term outcomes from GeparNuevo trial have been published in Annals of Oncology.
-
03.08.2022 GBG-Research at EMSO 2022
We are proud to present our research at ESMO Congress 2022 in Paris.
-
31.07.2022 July 2022: HER2-positive breast cancer patients with brain metastases have the best prognosis compared to other tumor subtypes
We are pleased to inform you that a subanalysis of HER2-positive breast cancer patients with brain metastasis from the BMBC registry has been published in ESMO Open.
-
14.07.2022 Eight-year data from APHINITY study presented
Eight-year data from APHINITY study show Roche’s Perjeta-based regimen continues to reduce the risk of disease returning for people with HER2-positive early breast cancer
-
30.06.2022 June 2022: Pregnancy does not impact the effectiveness of chemotherapy for breast cancer.
We are pleased to inform you that outcome of pregnant breast cancer patients treated with chemotherapy versus non-pregnant controls has been published in European Journal of Cancer
-
31.05.2022 May 2022: Effect of denosumab added to 2 different nab-paclitaxel regimens as neoadjuvant therapy for primary breast cancer – results from GeparX trial
We are pleased to inform you that primary results from GeparX trial have been published in JAMA Oncology.
-
24.05.2022 Ovarian Toxicity Assessment
In a paper in "The Breast" we discuss the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials.
-
12.05.2022 GBG Research at ASCO 2022
We are happy to present our research at the ASCO Annual meeting June 2022.
-
30.04.2022 April 2022: Adjuvant pertuzumab significantly improved invasive disease-free survival for HER2-positive, N-positive early breast cancer in the APHINITY trial
We are pleased to inform you that a STEPP analysis of the updated data from the APHINITY trial has been published in European Journal of Cancer
-
22.04.2022 ESMO Breast Cancer Meeting
GBG research at ESMO Breast Cancer Meeting 2022 May 3rd to 5th in Berlin.
-
05.04.2022 2022 ESMO Breast Cancer Award for Sibylle Loibl
ESMO has announced that the 2022 ESMO Breast Cancer Award is presented to Sibylle Loibl for her exceptional contribution to clinical research in breast cancer.
-
31.03.2022 March 2022: Long-term outcomes from the BrighTNess trial support inclusion of carboplatin in neoadjuvant chemotherapy for early-stage TNBC.
We are pleased to inform you that 4-year follow-up data from the BrighTNess trial has been published in Annals of Oncology.
